Ilumetri

Tildrakizumab, the active ingredient in Ilumetri, is a IL-23 inhibitor presented as a subcutaneous formulation for subcutaneous use. It is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients. GNH USA supplies Ilumetri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ilumetri targets the IL‑23 pathway, a key driver of inflammatory skin disease. - Moderate-to-severe plaque psoriasis: reduces the severity and extent of psoriatic plaques, improving skin clearance and quality of life.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Headache: transient, usually mild. - Diarrhea: occasional loose stools. - Fatigue: feeling of tiredness without exertion. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Opportunistic infections: signs of fungal or bacterial infection. - New onset or worsening inflammatory bowel disease. - Hepatic abnormalities: elevated liver enzymes. - Malignancies: rare reports of skin or lymphoid cancers. - Cardiovascular events: rare cases of myocardial infarction or stroke.

Before initiating therapy, clinicians should assess patient history and monitor for specific risks. - Infection screening: evaluate for active or latent infections, especially tuberculosis. - Vaccination status: administer required vaccines before treatment; avoid live vaccines during therapy. - Pregnancy and lactation: discuss potential risks; use only if benefits outweigh risks. - Concomitant immunosuppression: consider increased infection risk when combined with other immunosuppressants. - Monitoring: regular laboratory tests for liver function and complete blood count. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tildrakizumab may interact with other agents that affect immune function. Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection. - Other biologic immunomodulators: increased risk of severe infections.

Moderate Interactions (Monitor Closely): - Systemic immunosuppressants (e.g., methotrexate): monitor infection signs. - Antifungal agents: watch for additive immunosuppression. - Cytokine‑targeting therapies: assess overlapping immune effects.